Over-Expression of PDGFR-β Promotes PDGF-Induced Proliferation, Migration, and Angiogenesis of EPCs through PI3K/Akt Signaling Pathway by Wang, Hang et al.
Over-Expression of PDGFR-b Promotes PDGF-Induced
Proliferation, Migration, and Angiogenesis of EPCs
through PI3K/Akt Signaling Pathway
Hang Wang
1., Yangguang Yin
2., Wei Li
1, Xiaohui Zhao
1, Yang Yu
1, Jinkun Zhu
1, Zhexue Qin
1, Qiang
Wang
1, Kui Wang
1, Wei Lu
1, Jie Liu
1, Lan Huang
1*
1Institute of Cardiovascular Science Xinqiao Hospital, Third Military Medical University, Shapingba District, Chongqing, People’s Republic of China, 2Emergency
Department, Xinqiao Hospital, Third Military Medical University, Shapingba District, Chongqing, People’s Republic of China
Abstract
The proliferation, migration, and angiogenesis of endothelial progenitor cells (EPCs) play critical roles in postnatal
neovascularization and re-endothelialization following vascular injury. Here we evaluated whether the over-expression of
platelet-derived growth factor receptor-b (PDGFR-b) can enhance the PDGF-BB-stimulated biological functions of EPCs
through the PDGFR-b/phosphoinositide 3-kinase (PI3K)/Akt signaling pathway. We first confirmed the expression of
endogenous PDGFR-b and its plasma membrane localization in spleen-derived EPCs. We then demonstrated that the
PDGFR-b over-expression in EPCs enhanced the PDGF-BB-induced proliferation, migration, and angiogenesis of EPCs. Using
AG1295 (a PDGFR kinase inhibitor), LY294002 (a PI3K inhibitor), and sc-221226 (an Akt inhibitor), we further showed that the
PI3K/Akt signaling pathway participates in the PDGF-BB-induced proliferation, migration, and angiogenesis of EPCs. In
addition, the PI3K/Akt signaling pathway is required for PDGFR-b over-expression to enhance these PDGF-BB-induced
phenotypes.
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Introduction
Endothelial injury is a principal factor that contributes to
atherosclerosis and restenosis after percutaneous coronary inter-
vention [1,2]. Endothelial repair and regeneration is therefore a
crucial step in treating vascular diseases and a potential target for
the therapy. However, advances in therapeutics are limited due to
the insufficient de novo differentiation of pre-existing mature
endothelial cells (ECs) [3]. Recently, many basic and clinical
studies have indicated that the bone marrow-derived endothelial
progenitor cells (EPCs) can enter the circulation, differentiate into
ECs, and play important roles in postnatal neovascularization and
regeneration of the endothelial monolayer [3,4,5,6,7]. Indeed,
EPCs play a fundamental role in neoangiogenesis and re-
endothelialization after vascular injury as well as during tumor
angiogenesis [8,9,10,11,12]. Consequently, controls on the
number and functional activity of EPCs have become an area of
intense investigation.
Platelet-derived growth factor (PDGF) was initially identified in
the serum and platelets as a major mitogen for smooth muscle cells
and fibroblasts in vitro [13,14]. PDGF comprises four polypeptides
A, B, C, and D, which assemble into disulfide-linked homodimers
or heterodimers (PDGF-AA, -BB, -CC, -DD, or PDGF-AB).
These five PDGF dimers bind to two PDGF receptors (PDGFR)-a
and –b with different affinities [15]. PDGFRs dimerize upon
PDGF binding and PDGF-BB is the only PDGF dimer that binds
with high affinity to all three PDGFR isoforms: PDGFR-aa,
PDGFR-bb, and PDGFR-ab. Previous studies have indicated that
the interaction between PDGF-BB and PDGFR-b is key for the
proliferation and migration of pericytes and the development of a
functional vasculature [16,17]. Moreover, PDGF-BB and
PDGFR-b interaction induces the phosphorylation of PDGFR
and activates phosphoinositide 3-kinase (PI3K) [18].
The PI3K signaling pathway contributes to a number of cell
processes, including cell proliferation, survival, motility, and
angiogenesis [19]. Several studies showed that the activation of
the PI3K/Akt pathway may play a major role in the statin-
induced increase in EPC levels [20,21,22]. In addition to PDGF,
vascular endothelial growth factor (VEGF) [23], erythropoietin
[24], and estrogen [25,26] can also activate the PI3K/Akt
pathway.
To date, the role of PDGFR-b in EPCs still remains largely
unknown. In this study, we transfected PDGFR-b into spleen-
derived EPCs and found that PDGFR-b over-expression promot-
ed the PDGF-BB-induced proliferation, migration, and angiogen-
esis of EPCs. We further demonstrated that the PI3K/Akt
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e30503signaling pathway was critical for both the PDGF-BB-induced
activities of EPCs and the promotive effects of PDGFR-b over-
expression on the PDGF-BB-induced EPC activities.
Materials and Methods
Ethics statement
All procedures were in compliance with the Ethic Committee of
Third Military Medical University and the National Institute of
Health Guide for the Care and Use of Laboratory Animals.
EPC culture and characterization
Mouse spleen-derived EPCs were cultured and characterized as
previously described [27]. Briefly, spleens were harvested from
male C57BL/6 mice (6 to 8 weeks of age, 20 to 25 g of weight,
Chongqing, China) and then mechanically minced. Spleen-
derived mononuclear cells (MNCs) were isolated using density
gradient centrifugation at 2000 g for 20 min. After three times
rinses, cells were plated in gelatin-coated cell culture flasks and
cultured at 37uC in a 5% CO2 atmosphere with Dulbecco’s
Modified Eagle Medium: nutrient mixture F-12 (DMEM/F-12)
culture medium (Gibco BRL, NY, USA) supplemented with 20%
fetal calf serum (FCS, Gibco BRL, NY, USA), 10 ng/mL VEGF
(R&D Systems, Minneapolis, MN, USA), 100 U/mL penicillin,
and 100 U/mL streptomycin. Starting from four days after
culturing, the medium was changed every 3 days. Only attached
cells were used for further experiments.
For characterization, differentiating cells were incubated with
2.4 mg/mL acLDL-DiI (Invitrogen, CA, USA) for at 37uC for 4 h
and fixed with 4% paraformaldehyde (PFA) for 10 min. After
rinsed with phosphate-buffered saline (PBS), cells were incubated
with 10 mg/mL FITC-UEA-1 (Sigma-Aldrich, St Louis, MO,
USA) for 1 h. Cells that were positive for both acLDL-DiI and
UEA-1 were identified as EPCs. Additionally, the phenotypes of
EPCs were determined by flow cytometry (FACS). Cells (1610
6)
were incubated with the following monoclonal antibodies: FITC-
conjugated anti-Sca-1 (abCAM, Cambridge, MA, USA), PE-
conjugated anti-VEGFR-2 (eBiosciences, San Diego, CA, USA),
or their corresponding isotype controls (eBiosciences).
Semi-quantitative RT-PCR
MNCs were cultured for 4, 7, 14, or 21 days as described above
to obtain EPCs. To examine the mRNA expression level of
PDGFR-b in transfected cells, EPCs were harvested 72 h post-
transfection. Total RNA was extracted with Trizol (Invitrogen)
according to the manufacturer’s instructions. cDNA was obtained
through RT-PCR using a PrimeScript
TM RT reagent kit (Takara,
Dalian, China), with the total RNA as template, and then
amplified. The primers were as follows: PDGFR-b sense: 59
CCGGCGCTGGCGAGTTAGTTT 39; PDGFR-b antisense: 59
ACACCTACTTTTGAGGTCTCTGCAGG 39; product length:
296 bp. GAPDH sense: 59 AACTTTGGCATTGTGGAAGGG-
CTC 39; GAPDH antisense: 59 ACCCTGTTGCTGTAGCCG-
TATTCA 39; product length: 473 bp. All primers were synthe-
sized by Invitrogen (Shanghai, China).
Western blot
MNCs were cultured for 4, 7, 14, or 21 days as described above
to obtain EPCs. To examine the protein expression level of
PDGFR-b in transfected cells, EPCs were harvested 72 h post-
transfection. Cells from the transfection groups were used to
examine the expression levels of proteins involved in the signaling
pathways. The protein content was determined using the Bradford
method. Equal amounts of protein were subjected to SDS-PAGE
and transferred to PVDF membranes. The membranes were
blocked with 5% non-fat milk, probed with anti-PDGFR-b, anti-
phospho-PDGFR-b (abCAM), anti-GAPDH, anti-PI3 kinase p85,
anti-phospho-PI3 kinase p85, anti-Akt, or anti-phospho-Akt (Cell
Signaling Biotechnology, Beverly, MA, USA), and then stained
with horseradish peroxidase-coupled secondary antibodies. Pro-
tein bands were visualized using enhanced chemiluminescence
(Amersham Pharmacia Biotech., UK) and quantified using
Quantity One software (Bio-Rad, USA).
Immunofluorescence
For fluorescence staining, EPCs were fixed with 4% PFA for
15 min. After three times rinses with PBS, cells were permeablized
with 0.1% Triton X-100 for 20 min. EPCs were first incubated
with an anti-PDGFR-b primary mAb (1:100) and then with a Cy3-
labeled secondary antibody (Beyotime, Shanghai, China). DAPI
was used to stain the nuclei of EPCs. Images were taken by laser
scanning confocal microscopy (LSCM, Leica).
Liposome-mediated cell transfection
The plasmid pEGFP-N2-PDGFR-b was kindly provided by Dr.
Shangcheng Xu at the Third Military Medical University. After
EPCs were cultured for 10 days and reached 60–70% confluence,
transfection was performed using a Lipofectamine
TM 2000 reagent
according to the instruction manual (Invitrogen). The DNA (mg) to
Lipofectamine
TM 2000 (mL) ratio was 1:2. Three groups of cells
were transfected: (1) control group: no plasmid; (2) pEGFP-N2
group: the plasmid pEGFP-N2; (3) pEGFP-N2-PDGFR-b group:
the plasmid pEGFP-N2-PDGFR-b.
Transfected cells can be identified using an in-vector marker,
EGFP. In order to evaluate the transfection efficiency, the number
of EGFP-positive cells was divided by the total number of EPCs in
the same area. Five random view-fields were counted, and the
average percentage of transfected cells was calculated.
Enzyme-Linked Immunosorbent Assay (ELISA) for
secreted PDGF-BB
PDGF-BB is a secretory protein, and the concentration of
PDGF-BB in the culture medium can be used to estimate the
expression level of PDGF-BB in EPCs. To compare the expression
level of PDGF-BB between the untransfected and transfected
EPCs, we measured the concentration of PDGF-BB in the
supernatant of the culture medium using ELISA (R&D Systems)
according to the manufacturer’s instructions. The supernatant of
culture medium were collected at 0, 24, 48 and 72 h after
transfection.
Table 1. Pattern/value association criterion.
Pattern Value
Individual cells, well separated 0
Cells begin to migrate and align themselves 1
Capillary tubes visible. No sprouting 2
Sprouting of new capillary tubes visible 3
Closed polygons begin to form 4
Complex mesh-like structures develop 5
Cite: In Vitro Angiogenesis Assay Kit instruction.
doi:10.1371/journal.pone.0030503.t001
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To examine the effects of exogenous PDGFR-b transfection and
different concentrations of PDGF-BB stimulation on the biological
functions of EPCs, the three groups of EPCs from PDGFR-b
transfection (the control group, the pEGFP-N2 group, and the
pEGFP-N2-PDGFR-b group) were treated with PDGF-BB
(Peprotech, USA) of different concentrations (0, 10, 20, 40, 80,
or 160 ng/mL) for 24 h. Since results from the control group and
the pEGFP-N2 group were similar, only the control group was
used for subsequent experiments.
To examine whether the PDGFR-b/PI3K signaling pathway is
involved in PDGF-BB-induced biological functions of EPCs, the
two groups of EPCs without PDGFR-b transfection (the control
group and the pEGFP-N2-PDGFR-b group) were treated as
follows: untreated for 24 h; treated with PDGF-BB at maximal
effective concentration for 24 h; or pretreated with 20 mM
tyrphostin AG1295 (Sigma-Aldrich), 30 mM LY294002 (Cell
Signaling Biotechnology), or 30 mM sc-221226 (Santa Cruz
Biotechnology, Santa Cruz, CA, USA), respectively, for 1 h before
treated with PDGF-BB at maximal effective concentration for 24 h.
Figure 1. Spleen-derived MNCs differentiate into cells with characteristics of endothelial progenitor cells after cultured in vitro. (A)
After 4–7days in culture, spleen-derived MNCs exhibited a spindle-shaped, endothelial cell-like morphology. Scale bar=100 mm. (B) After 10 days,
cells formed cord-like structures. Scale bar=100 mm. (C) After 20 days, cells became confluent, and looked like cobblestones. Scale bar=200 mm.
(D,E,F) Spleen-derived MNCs showed uptake of acetylated LDL (D) and UEA-1 binding (E) after 4 days in culture. Most adherent cells were LDL and
UEA-1 double positive (91.261.8%; n=5; three random fields per well). Scale bar=75 mm. (G) FACS analysis of cultured spleen-derived MNCs for
FITC-Sca-1 (a stem/progenitor cell marker), generating a positive rate of 71.760.93% (n=3). (H) FACS analysis of cultured spleen-derived MNCs for PE-
VEGFR-2 (an endothelial cell marker), generating a positive rate of 52.4969.27% (n=3). The left peak in each box denotes corresponding negative
isotype control labeling, and the positive gate M1 is shown.
doi:10.1371/journal.pone.0030503.g001
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EPC proliferation was examined by the colorimetric MTS assay
(Cell Titer 96 Aqueous, Promega). EPCs were seeded in 96-well
plates in quintuplicate at a cell density of 5610
3/well and cultured
in DMEM/F12 containing 10% FCS. 48 h later, MTS (20 mL/
well) was added for another 4 h incubation at 37uC. The optical
density (OD) at 490 nm was recorded with a 96-well plate reader.
EPC migration assay
The migration of EPCs was assayed using a Transwell system
(Corning Costar, USA) containing 8 mm polycarbonate filter
inserts in 24-well plates. 2610
5 cells from the control group,
pEGFP-N2 group, or pEGFP-N2-PDGFR-b group without
pretreatment or pretreated with AG1295, LY294002, or sc-
221226, respectively, for 30 min in 200 mL serum-free DMEM/
F12 were placed in the upper chamber. DMEM/F12 containing
10% FCS (500 mL) with or without PDGF-BB was filled in the
lower chamber. After 16 h in culture, cells on the bottom of the
Transwell membrane were fixed with 4% PFA at 37uC for 20 min
and stained with 1% crystal violet at 37uC for 5 min. The number
of migrating cells on the bottom of the Transwell in 6 randomly
selected high power fields (6200) was counted manually. Results
were representative of five independent experiments.
EPC tube-formation assay
EPC’s participation in tube-like formation was evaluated with
the In Vitro Angiogenesis Assay Kit (Chemicon, Canada & USA).
EPCs were treated as in the migration assay, harvested,
resuspended, and reseeded into 96 well plates coated with 50 mL
of diluent ECMatrix
TM solution at a cell density of 1610
4/well.
After incubation at 37uC for 6 h, EPC tube-like formation was
observed by microscopy, and visual patterns were defined based
on the pattern/value association criterion (Table 1). Five randomly
selected high power view-fields (6200) per well were assessed and
the values averaged.
Statistical analysis
All data were expressed as mean 6 S.D. Statistical analyses
were performed with SPSS 13.0 software. Comparisons between
multiple groups were tested by Multi-Way ANOVA or One-Way
ANOVA. Comparisons between groups were performed using
Fisher’s LSD test. A probability value of P,0.05 was considered
statistically significant.
Results
Characterization of spleen-derived EPCs
Isolated spleen-derived MNCs exhibited a spindle-shaped
morphology after cultured for 4–7 days (Fig. 1A), formed cord-
like structures after 10 days (Fig. 1B), and showed like cobblestone
like structures after 20 days (Fig. 1C). Most attached cells
(91.261.8%) were double positive for both acLDL-DiI and
UEA-1 and identified as EPCs (Figs. 1D, E, and F). In addition,
71.760.93% of these cells expressed mouse stem-cell marker Sca-
1 (Fig. 1G), and 52.4969.27% expressed endothelial cell marker
VEGFR-2 (Fig. 1H).
Endogenous PDGFR-b expression and localization in
EPCs
The expression of PDGFR-b in EPCs progressively increased
with differentiation time as shown by semi-quantitative RT-
Figure 2. PDGFR-b expression and localization in EPCs. (A)RT- PCR analysis of PDGFR-b (296 bp) in EPCs at Day 4, 7, 14, and 21. (B) Western
blot analysis of PDGFR-b protein (124 kDa) in EPCs at Day 4, 7, 14, and 21. (C, D, E) Subcellular localization of PDGFR-b in EPCs. EPCs were stained for
PDGFR-b (C) and nuclei were stained with DAPI (D). PDGFR-b was localized predominantly to the plasma membrane of EPCs. PDGFR-b positive cells
in the total cells were 88.664.3% (n=5; three random fields per well).Scale bar=25 mm.
doi:10.1371/journal.pone.0030503.g002
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14, and 21. Additionally, the subcellular localization of PDGFR-b
in EPCs was investigated by immunofluorescence. PDGFR-b was
found to be localized in the plasma membrane of the
cells(88.664.3%) (Figs. 2C, D, and E). We concluded from these
observations that PDGFR-b is expressed in the primary EPCs.
Over-expression of PDGFR-b in transfected EPCs
EPCs were transfected with either pEGFP-N2 or pEGFP-N2-
PDGFR-b. 21 h after transfection, EGFP expression was detected
by laser scanning confocal microscopy in both the pEGFP-N2
group and pEGFP-N2-PDGFR-b group, while no EGFP was
detected in the control group (data not shown). The transfection
efficiency was about 50–60% (Figs. 3A, B, and C). 72 h post-
transfection, the level of PDGFR-b in the pEGFP-N2-PDGFR-b
group was significantly increased compared to the control group
or the pEGFP-N2 group, as shown by semi-quantitative RT-PCR
(Fig. 3D) and Western blot (Figs. 3E) (P,0.01).
Secretion of PDGF-BB by EPCs
In the next step, we sought to determine whether PDGFR-b
transfection could change the secretionofPDGF-BB.Tothis end,we
compared the concentration of PDGF-BB in the supernatant of
culture medium between the untransfected cells and cells
Figure 3. Overexpression of PDGFR-b in transfected EPCs. (A,B,C) Transfected cells can be identified using an in-vector marker, EGFP 21 h
after transfection, the expression of EGFP was detected by laser scanning confocal microscopy in the pEGFP-N2-PDGFR-b group (A), and nuclei were
stained with DAPI (B). The transfection efficiency (number of green cells/total number of cells) was about 50-60%. Scale bar=75 mm. (D,E) 72 h post-
transfection, PDGFR-b mRNA (D) and protein levels (E) in the pEGFP-N2-PDGFR-b group were significantly higher than in the control group or pEGFP-
N2 group.* P,0.01 vs. control or pEGFP-N2; NS, no significant vs. control (n=3).
doi:10.1371/journal.pone.0030503.g003
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PLoS ONE | www.plosone.org 5 February 2012 | Volume 7 | Issue 2 | e30503Figure 4. ELISA of PDGF-BB secreted by EPCs in response to PDGFR-b transfection. The concentration of PDGF-BB in the supernatant of
culture medium was measured using ELISA. The concentration of PDGF-BB was significantly lower in the pEGFP-N2-PDGFR-b group than in the
control or pEGFP-N2 group at 48 h and 72 h post-transfection. * P,0.01 vs. control or pEGFP-N2 (n=6).
doi:10.1371/journal.pone.0030503.g004
Figure 5. Effects of PDGFR-b overexpression on PDGF-BB-induced EPC proliferation. EPCs (untransfected,or transfected with either
pEGFP-N2 or pEGFP-N2-PDGFR-b) were incubated with PDGF-BB of different concentrations.EPC proliferation was examined by the MTS assay.
* P,0.01 vs. pEGFP-N2-PDGFR-b cells under 0 ng/mL PDGF-BB stimulation.
doi:10.1371/journal.pone.0030503.g005
PDGFR-b Promotes Function of EPCs
PLoS ONE | www.plosone.org 6 February 2012 | Volume 7 | Issue 2 | e30503Figure 6. Effects of PDGFR-b overexpression on PDGF-BB-induced EPC migration. EPCs (untransfected,or transfected with either pEGFP-N2
or pEGFP-N2-PDGFR-b) were incubated with PDGF-BB of different concentrations. EPC migration was examined by the Transwell system. * P,0.01 vs.
pEGFP-N2-PDGFR-b cells under 0 ng/mL PDGF-BB stimulation.
doi:10.1371/journal.pone.0030503.g006
Figure 7. Effects of PDGFR-b overexpression on PDGF-BB-induced EPC tube formation. EPCs (untransfected,or transfected with either
pEGFP-N2 or pEGFP-N2-PDGFR-b) were incubated with PDGF-BB of different concentrations. EPC tube formation was examined by the In Vitro
Angiogenesis Assay Kit. * P,0.01 vs. pEGFP-N2-PDGFR-b cells under 0 ng/mL PDGF-BB stimulation.
doi:10.1371/journal.pone.0030503.g007
PDGFR-b Promotes Function of EPCs
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showedthatincellexpressingpEGFP-N2-PDGFR-b,theconcentra-
tion of soluble PDGF-BB significantly reduced to 11.062.7 pg/ml
(n=6) at 48 h post-transfection, and 6.362.0 pg/ml (n=6) at 72 h
post-transfection (Fig. 4) (P,0.01).
Effects of PDGFR-b over-expression on PDGF-BB-induced
EPC proliferation
We next used the MTS assay to examine how the PDGFR-b
over-expression affected the EPC proliferation stimulated by
recombinant PDGF-BB. The main effects of concentration
(F=220.880, P,0.01) and group (F=349.826, P,0.01), as well
as their interaction (F=88.717, P,0.01), were all significant. The
maximum proliferation induced by recombinant PDGF-BB
occurred at 20 ng/mL in both the control and pEGFP-N2 groups
andat 80 ng/mLinthepEGFP-N2-PDGFR-b group (Fig.5).Since
no difference was observed between the control and pEGFP-N2
groups, in subsequent proliferation experiments, only the control
group and the pEGFP-N2-PDGFR-b group were compared, and
the two maximum proliferation concentrations indentified here
were used for the two groups to stimulate proliferation, respectively.
Interestingly, in the control and pEGFP-N2 groups, EPC
proliferation remained unchanged under different concentrations
of PDGF-BB (P.0.05) (Fig. 5). In contrast, EPC proliferation
increased significantly with increase in PDGF-BB concentra-
tion(P,0.05), indicating that PDGF-BB-induced EPC proliferation
is enhanced by PDGFR-b over-expression.
Effects of PDGFR-b over-expression on PDGF-BB-induced
EPC migration
We further used the Transwell system to examine the effects of
PDGFR-b over-expression on PDGF-BB-induced EPC migration.
The main effects of concentration (F=605.098, P,0.01) and
group (F=1422.843, P,0.01), as well as their interaction
(F=327.163, P,0.01) were all significant. The maximum
migration induced by recombinant PDGF-BB occurred at
20 ng/mL in both the control and pEGFP-N2 groups and at
80 ng/mL in the pEGFP-N2-PDGFR-b group (Fig. 6). Since no
difference was observed between the control and pEGFP-N2
groups, in subsequent migration experiments, only the control
group and the pEGFP-N2-PDGFR-b group were compared, and
the maximum migration concentration indentified were used to
stimulate migration for the two groups. No significant difference in
PDGF-BB-induced EPC migration was observed following
increase in PDGF-BB concentration in the control and pEGFP-
N2 groups (P.0.05) (Fig. 6). In contrast, EPC migration increased
significantly with increase in PDGF-BB concentration (P,0.05),
indicating that PDGF-BB-induced EPC migration was also
enhanced by PDGFR-b over-expression.
Effects of PDGFR-b over-expression on PDGF-BB-induced
EPC tube-formation
We then used the In Vitro Angiogenesis Assay Kit to examine
the effects of PDGFR-b over-expression on the tube formation of
EPC. The main effects of concentration (F=60.861, P,0.01) and
group (F=117.979, P,0.01), as well as their interaction
(F=26.599, P,0.01), were all significant. The maximum tube
formation induced by recombinant PDGF-BB occurred at 20 ng/
mL for both the control and pEGFP-N2 groups, and at 80 ng/mL
for the pEGFP-N2-PDGFR-b group (Fig. 7). Since no difference
was observed between the control and pEGFP-N2 groups, in the
subsequent tube-formation experiments, only the control group
and the pEGFP-N2-PDGFR-b group were compared, and the
maximum tube-formation concentration indentified here were
used for the two groups to stimulate tube-formation, respectively.
There were no significant changes in PDGF-BB-induced EPC
tube-formation with increase in PDGF-BB concentration in the
control and pEGFP-N2 groups (P.0.05) (Fig. 7). In contrast, EPC
tube-formation increased significantly with increase in PDGF-BB
concentration(P,0.05), indicating that PDGF-BB-induced EPC
tube-formation is also enhanced by PDGFR-b over-expression.
The role of PI3K/Akt pathway in PDGF-BB-induced
proliferation, migration, and tube-formation of EPCs
PDGFR-b and the activation of PI3K/Akt are both important
for PDGF-BB to function [18,28,29]. We thus further tested
whether the PI3K/Akt signaling pathway plays a role in the PDGF-
BB-induced proliferation, migration, and angiogenesis of EPCs and
whether this role is also important in the promotive effects of
PDGFR-b over-expression on these PDGF-BB-induced pheno-
types. AG1295(aselectiveinhibitorofPDGFR), LY294002(a PI3K
inhibitor), and sc-221226 (an Akt inhibitor) were used to inhibit the
activation of PDGFR or the PI3K/Akt signaling pathway.
Interestingly, the PDGF-BB-induced proliferation (Fig. 8A),
migration (Fig. 8B), and angiogenesis (Fig. 8C) in the control group
(by 20 ng/mL PDGF-BB) and the pEGFP-N2-PDGFR-b group
(by 80 ng/mL PDGF-BB) were all significantly inhibited by the
pretreatment of AG1295, LY294002, or sc-221226. These results
indicated that the PI3K/Akt signaling pathway participated in the
PDGF-BB-induced proliferation, migration (Fig. 9), and angio-
genesis (Fig. 10) of EPCs.
In addition, the PI3K/Akt signaling pathway was required for
PDGFR-b over-expression to enhance these PDGF-BB-induced
phenotypes.
Various inhibitors attenuate PDGF-BB-stimulated
phosphorylation of PDGFR-b, PI3K, and Akt
The binding of PI3K to PDGFR-b has been shown to be
important for the receptor mediated cell responses [30,31]. To
investigate whether the PDGFR-b/PI3K/Akt signaling pathway
was involved in EPCs, the phosphorylation/activation levels of
PDGFR-b, PI3K, and Akt were examined by western blot after
exposure to PDGF-BB. Exogenous stimulation with PDGF-BB
(20 ng/mL for the control cells and 80 ng/mL for the pEGFP-N2-
PDGFR-b transfected cells) markedly upregulated the phospho-
tyrosine levels of PDGFR-b (Fig. 11A), PI3K (Fig. 11B), and Akt
(Fig. 11C), confirming the activation of the PDGFR-b/PI3K/Akt
signaling pathway.
Figure 8. The role of PI3K/Akt pathway in PDGF-BB-induced proliferation, migration, and tube formation of EPCs. (A, B, C) Cells in
the control group (bright bars, left half) and the pEGFP-N2-PDGFR-b group (dark bars, right half) were without pretreatment or pretreated with
AG1295, LY294002, or sc-221226 for 1 h and then treated with 20 ng/mL PDGF-BB (for the control cells) or 80 ng/mL PDGF-BB (for the pEGFP-N2-
PDGFR-b cells). PDGF-BB-induced proliferation (A), migration (B), and angiogenesis (C) of EPCs were significantly inhibited by pretreatment with
AG1295, LY294002, or sc-221226. ** P,0.01 vs. control cells under 0 ng/mL PDGF-BB stimulation; * P,0.01 vs. control cells under 20 ng/mL PDGF-BB
stimulation. ## P,0.01 vs. pEGFP-N2-PDGFR-b cells under 0 ng/mL PDGF-BB stimulation; # P,0.01 vs. pEGFP-N2-PDGFR-b cells under 80 ng/mL
PDGF-BB stimulation.
doi:10.1371/journal.pone.0030503.g008
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PLoS ONE | www.plosone.org 9 February 2012 | Volume 7 | Issue 2 | e30503Figure 9. Representative photos of PDGF-BB-induced EPC migration by PI3K/Akt pathway. Cells in the control group (A) and the pEGFP-
N2-PDGFR-b group (B) were without pretreatment or pretreated with AG1295, LY294002, or sc-221226 for 1 h and then treated with 20 ng/mL PDGF-
BB (for the control cells) or 80 ng/mL PDGF-BB (for the pEGFP-N2-PDGFR-b cells). Scale bar=100 mm.
doi:10.1371/journal.pone.0030503.g009
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PLoS ONE | www.plosone.org 10 February 2012 | Volume 7 | Issue 2 | e30503Figure 10. Representative photos of PDGF-BB-induced EPC angiogenesis in vitro by PI3K/Akt pathway. Cells in the control group (A)
and the pEGFP-N2-PDGFR-b group (B) were without pretreatment or pretreated with AG1295, LY294002, or sc-221226 for 1 h and then treated with
20 ng/mL PDGF-BB (for the control cells) or 80 ng/mL PDGF-BB (for the pEGFP-N2-PDGFR-b cells). Scale bar=100 mm.
doi:10.1371/journal.pone.0030503.g010
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PLoS ONE | www.plosone.org 12 February 2012 | Volume 7 | Issue 2 | e30503The PDGFR inhibitor AG1295 (20 mM) significantly blocked
the increase in p-PDGFR-b (Fig. 11A), p-PI3K (Fig. 11B), and p-
Akt (Fig. 11C) in the control cells in response to PDGF-BB
stimulation, indicating that PDGFR was critical for the PDGF-
mediated activation of PI3K/Akt. In pEGFP-N2-PDGFR-b
transfected cells, AG1295 also decreased the increase in p-
PDGFR-b (Fig. 11A). However, the residual level of p-PDGFR-b
under AG1295 treatment could still be high enough to stimulate
the downstream PI3K/Akt signaling, generating p-PI3K (Fig. 11B)
and p-Akt (Fig. 11C) at a level that was not significantly different
from that in the absence of AG1295.
The PI3K inhibitor LY294002 (30 mM) significantly blocked
the phosphorylation of PI3K (Fig. 11B) and Akt (Fig. 11C) in both
control cells and pEGFP-N2-PDGFR-b transfected cells in
response to PDGF-BB stimulation. In addition, the Akt inhibitor
sc-221226 (30 mM) significantly blocked the phosphorylation of
Akt (Fig. 11C) in both control cells and pEGFP-N2-PDGFR-b
transfected cells in response to PDGF-BB stimulation.
Discussion
EPCs are a special type of bone marrow-derived progenitor
cells, showed EC features, and can differentiate into ECs [3].
EPCs have been indicated to play important roles in neovascu-
larization and re-endothelialization. During postnatal neovascu-
larization, blood vessels are regenerated from the proliferation
and migration of not only ECs [3] but also EPCs [32,33].
Infusion of ex vivo expanded EPCs has been shown to improve
neovascularization in animal ischemia models [34]. In addition,
EPCs play important roles in the regeneration of injured
endothelium. The levels of EPCs can reflect vascular repair
capacity and have been shown to be associated with endothelial
function [8]. As EPCs contribute to neovascularization and
reendothelialization, augmenting the number of EPCs and
improving the functional activity of these cells may be an
attractive therapeutic agents.
PDGF-BB has been well documented in contributing to
vascular repair/remodeling in humans and animal models after
vascular injury (recently reviewed in [35]). For instance, PDGF-BB
expression is up-regulated in smooth muscle cells in rat carotid
arteries after balloon injury to stimulate the proliferation and
migration of small muscle cells [36]. On the other hand, inhibition
of PDGF-BB signaling has been shown to reduce vascular repair/
remodeling after angioplasty [37,38,39]. In the present study, we
first confirmed the endogenous expression of PDGFR-b, and
identified that the endogenous PDGFR-b was localized to the
plasma membrane of spleen-derived EPCs. Furthermore, we
found that the over-expression of PDGFR-b can promote the
proliferation, migration, and angiogenesis of EPCs through
enhancing the PDGF-BB bioavailability. Our results indicated
that the transplantation of PDGFR-b over-expressed EPCs can be
used as a novel therapy for the treatment of vascular injury. For
instance, PDGFR-b transfected EPCs can be injected into the sites
of vascular injury, where the PDGF-BB expression has been up-
regulated. Based on our study, we propose that the exogenous
PDGFR-b over-expression and the locally up-regulated PDGF-BB
stimulation can take combined effects to amplify the activity of
PDGF-BB stimulated EPCs and subsequently attenuate endothe-
lial injury.
We note that PDGF and PDGFR also play roles in the
autocrine stimulation of tumor growth as well as the paracrine
stimulation of tumor-associated angiogenesis in a variety of human
epithelial cancers (recently reviewed in [40]). For example, in glial
tumors, the PDGF levels in tumor cells are correlated with the
tumor grade [41]. The high expression level of PDGFR-b has
been observed in ECs of gliomas [42] and breast cancers [43].
Consequently, anti-PDGFR-b therapies have been suggested in
cancers where PDGFR-b-positive ECs are present [40].These
observations indicated that the combined application of PDGFR-b
and PDGF-BB might increase the risk of tumor progression.
Hence, future work will be focused on the validation and
optimization of this promising approach to optimize its efficacy
in the treatment of vascular injury while maximally reducing the
risk of tumor progression.
After tyrosine phosphorylation, PDGFR-b recruits PI3K,
phospholipase Cc1, Src family kinase, and phosphotyrosine
phosphatase SHP-2 [44]. PI3K further activates Akt, which
serves as a multifunctional regulator of cell survival, growth, and
glucose metabolism [19,45]. Since the simvastatin-induced
phosphorylation of Akt in EPCs was first reported [20], several
studies have shown that PI3K/Akt signaling is also required
under other stimulations, including VEGF [23], estrogen
[25,26], and red wine [46], indicating that the PI3K/Akt
pathway is important in EPC regulation. However, it remains
unclear the role of PI3K/Akt signaling in EPC proliferation,
migration, and angiogenesis stimulated by PDGF-BB and its
receptor PDGFR-b.
In this study, we found that accompanying increased EPC
activities, the phosphotyrosine levels of PDGFR-b, PI3K, and Akt
all increased upon the stimulation of exogenous PDGF-BB.
Investigation using the inhibitors for these three molecules (i.e.
AG1295, LY294002, sc-221226) revealed that inhibiting the
activity and phosphorylation of PDGFR-b, PI3K, and Akt could
reduce PDGF-BB induced proliferation, migration, and angio-
genesis of both the control EPCs and the PDGFR-b over-
expressed EPCs. These observations indicated that the PI3K/Akt
signaling pathway is crucial for the EPC responses induced by
PDGF-BB and/or PDGFR-b. Our results are consistent with two
recent reports in which bFGF, PDGF-BB, and PDGFR-b can
promote the proliferation, migration and angiogenesis of EPCs
[47,48]. Importantly, in the present study, we demonstrated that
the PI3K/Akt signaling pathway is important for PDGF-BB to
affect EPCs. To our best knowledge, this is the first demonstration
on the mechanisms underlying PDGF signaling mediated
physiological changes of EPCs.
In conclusion, our study demonstrated that PDGFR-b, PI3K,
and Akt are important participants following PDGF stimulation
on EPCs. These molecules can promote re-endothelialization and
postnatal neovascularization after vascular injury, and thus can
be used as potential drug targets for the treatment of vascular
injury.
Figure 11. Pretreatment with various inhibitors attenuates PDGF-stimulated phosphorylation of PDGFR-b, PI3K, and Akt. (A, B, C)
Cells in the control group (bright bars) and the pEGFP-N2-PDGFR-b group (dark bars) were pretreated with AG1295, LY294002, or sc-221226 for 1 h
and then treated with 20 ng/mL PDGF-BB (for the control cells) or 80 ng/mL PDGF-BB (for the pEGFP-N2-PDGFR-b cells). PDGF-BB-induced phospho-
PDGFR-b (A), phospho-PI3K (B), and phospho-Akt (C) were normalized to total PDGFR-b, PI3K, or Akt, respectively. * P,0.05 and ** P,0.01 vs. control
cells under 20 ng/mL PDGF-BB stimulation. # P,0.05 and ## P,0.01 vs. pEGFP-N2-PDGFR-b cells under 80 ng/mL PDGF-BB stimulation.
doi:10.1371/journal.pone.0030503.g011
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